There was a distinct DNA copy number variations (CNV) signal in chromosome 2 especially in [[Gliosarcoma]]. The pathway enrichment of genes with CNV was suggested that the GBM and GSM shared the similar mechanism of tumor development. However, the CNV of some screened genes displayed a disparate form between GBM and GSM, such as [[AMP]], [[BEND2]], [[HDAC6]], [[FOXP3]], [[ZBTB33]], [[TFE3]], and [[VEGFD]]. It meant that GSM was a distinct subgroup possessing typical [[biomarker]]s. The pathways and copy number alterations detected in this study may represent key drivers in gliosarcoma [[oncogenesis]] and may provide a starting point toward targeted oncologic analysis with therapeutic potential
((Cheng CD, Chen C, Wang L, Dong YF, Yang Y, Chen YN, Niu WX, Wang WC, Liu QS, Niu CS. Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations. Anal Cell Pathol (Amst). 2022 Jun 15;2022:2376288. doi: 10.1155/2022/2376288. PMID: 35757013; PMCID: PMC9226978.))